Download Free Sample
Buy Now
Market Outlook
The Asia-Pacific prefilled syringes market, valued at USD 783 million in 2025, is projected to reach USD 858 million in 2026 and USD 1,606 million by 2035, representing a CAGR of 7.2% during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
Market Report: Key Takeaways
Market Size & Trends
- Glass syringes currently account for the largest share by barrel material, owing to the superior inertness and drug compatibility for biologics.
- Single-chamber syringes currently hold the largest share by chamber type, while dual-chamber syringes are expected to witness significant growth during the forecast period.
- Staked-needle syringes currently hold the largest share by needle system due to the fact that they are more convenient and offer reduced dead volume.
- Disposable syringes currently hold the largest market share and are also expected to grow at a faster pace during the forecast period as they minimize the cross-contamination risk, support infection control protocols, and align with safety and regulatory preferences across healthcare settings.
- China is expected to account for the largest share of the Asia-Pacific prefilled syringes market during the forecast period owing to the rapid expansion of biologics manufacturing, rising chronic disease burden, government healthcare investments, and increasing local production capacity.
Key Market Statistics
- Market Size in 2026: $858 Million
- Estimated Market Size in 2035: $1606 Million
- CAGR (2026-2035): 7.2%
- China: Fastest growing market in 2026
Market Introduction
PFS (prefilled syringes) are single-dose drug delivery systems in which a measured injectable medicine is supplied in a ready-to-administer syringe. Japan's PMDA defines a needled prefilled syringe as a single-use glass or plastic syringe used to administer a drug. The Asia-Pacific market spans therapeutic, specialty and cosmetic applications, including biologics, vaccines, proteins and small molecules, serving pharmaceutical manufacturers, healthcare providers and patients who require reliable injectable delivery.
Demand has expanded from hospital-based dose preparation toward ready-to-use formats that support biologics, vaccination and self-administration. Prefilled presentation reduces preparation steps, dosing errors, contamination exposure and drug waste relative to conventional vial-and-syringe workflows. The addressable vaccine-delivery base also remains substantial: WHO reported 94% DTP3 coverage in South-East Asia in 2025, while nearly 1.2 million children still missed their first routine vaccine.
Innovation is increasingly focused on drug-container compatibility and device integration. Suppliers now offer borosilicate glass systems with lower silicone and tungsten exposure as well as cyclic olefin polymer syringes that improve break resistance and design flexibility. Newer platforms also address high-viscosity biologics, autoinjector compatibility and low-particle requirements, helping developers move sensitive injectable products toward scalable commercial and home-use formats.
Adoption nevertheless depends on controlling interactions among the formulation, barrel, lubricant, elastomers, needle system and downstream device. These requirements become more demanding for concentrated biologics and combination products, where dimensional consistency, particles and functional performance can affect development timelines. Prefillable syringe selection and evaluation can take many months without assurance that every factor has been addressed. Wider adoption will require earlier container selection, stronger system-level data and scalable fill-finish capacity.
Market Segmentation
Based on the research, we have segmented the Asia-Pacific prefilled syringes market by purpose of syringe, type of molecule, therapeutic area, type of barrel fabrication material, number of barrel chamber, type of needle system, usability of syringe, and countries.
- By Purpose of Syringe: Therapeutic Syringes, Specialty Syringes, and Cosmetic Syringes
- By Type of Molecule: Antibodies, Vaccines, Proteins, Small Molecules, and Other Molecules
- By Therapeutic Area: Hematological Disorders, Infectious Diseases and Other Disorders
- By Type of Barrel Fabrication Material: Glass Syringes and Plastic Syringes
- By Number of Barrel Chamber: Single Chamber Syringes and Dual Chamber Syringes
- By Type of Needle System: Staked Needle Syringes and Luer Syringes
- By Usability of Syringe: Disposable Syringes and Reusable Syringes
- By Countries: China, Japan, India, South Korea, and Rest of Asia-Pacific
Asia-Pacific Prefilled Syringes Market Key Insights
What Are the Key Growth Drivers in the Asia-Pacific Prefilled Syringes Market?
- Rising Prevalence of Chronic Diseases: The Asia-Pacific region is witnessing a sharp rise in chronic conditions such as diabetes, cancer, and autoimmune disorders that require long-term injectable therapies. India had an estimated 89.8 million adults aged 20-79 years living with diabetes in 2024, while the IDF South-East Asia region had approximately 107 million adults living with diabetes. Aging populations in Japan, China, and South Korea further intensify demand for convenient, accurate, and ready-to-use prefilled syringe solutions.
- Expansion of Biologics and Biosimilars: The growing pipeline of monoclonal antibodies, proteins, vaccines, and specialty injectables is highly sensitive to contamination and dosing errors. These formats deliver superior stability, sterility, and precision compared with traditional vials. Expanding biosimilar manufacturing in China and India, coupled with rising approvals in prefilled presentations, is accelerating market growth across the region.
- Shift Toward Self-Administration and Home Healthcare: Patients and healthcare systems increasingly favor home-based treatment to lower costs and hospital visits. Prefilled syringes eliminate reconstitution and vial-drawing steps, improve dosing accuracy, enhance adherence, and enable safe unsupervised use for chronic conditions such as diabetes and autoimmune diseases. Acceptance of self-injection devices continues to rise across urban populations in China, India, Japan, and South Korea.
Recent Developments in Asia-Pacific Prefilled Syringes Market
- In September 2026, GSK received approval from Japan's Ministry of Health, Labour and Welfare for a prefilled syringe presentation of Shingrix. The ready-to-use format replaces the previous two-vial presentation that required manual reconstitution, simplifying vaccine preparation and administration for healthcare professionals.
- In August 2026, Sanofi-Aventis Singapore received Health Sciences Authority approval for Fluzone High-Dose in a pre-filled syringe presentation. The approval adds another vaccine-based prefilled syringe product to Singapore's market and expands the use of ready-to-administer delivery formats in adult immunization.
- In July 2026, CSL Behring launched Hizentra 20% subcutaneous immunoglobulin in a new 10 g/50 mL prefilled syringe presentation in Japan. The larger-volume presentation is intended to improve convenience for patients requiring higher immunoglobulin doses by reducing the number of individual syringe units needed.
Industry Experts on Asia-Pacific Prefilled Syringes Market
The Asia-Pacific prefilled syringes market is benefiting from the growing adoption of injectable therapies and increasing demand for practical, ready-to-use drug-delivery formats. The expansion of GLP-1 therapies is further creating opportunities for prefilled syringe presentations across the region.
Highlighting the growing role of prefilled syringes in expanding treatment options, Dr. Vikas Gupta, Chief Executive Officer of Alkem Laboratories, stated, "Semaglutide has the potential to change how we manage metabolic disorders. With the launch of our pre-filled syringes, we are widening the choice available to doctors and patients, alongside the pen options we have already introduced. In India, where we are seeing a continuous rise in disease burden, offering multiple, practical drug delivery formats is an important step in helping more patients start and stay on the therapy."
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:
- Founder and Chief Technology Officer, Mid-sized Organization, United Kingdom
- Chief Operating Officer, Very Large Organization, India
- Chief Executive Officer, Small-sized Medical Device Company
- Former Chief Commercial Officer, Large Organization, Germany
- Senior Director, Product Technology Services and Former Director, Pharmaceutical Delivery Systems Marketing, Very Large Organization, United States
- Former Head of R&D and Product Strategy, Mid-Sized Organization, Switzerland
- Senior Portfolio Director, Large Organization, United States
In addition, the market report includes transcripts of the following other third-party discussions:
- Founder, President and Chief Executive Officer; Chief Commercial Officer, Small Company, US
- Executive Director, Small Company, Canada
- President; Chief Commercial Officer, Mid-sized, US
- President and Co-founder, Small Company, US
- Director of Scientific Affairs, Large Company, US
- Senior Director of Drug Product Compliance, Large Company, South Korea
- Vice President of Global Operations; Vice President of Global Market Development, Very Large Company, US
- Head of Portfolio Strategy and Management, Small Company, US
- Senior Manager Regulatory Affairs, Very Large Company, US
- Technical Product Manager, Very Large Company, US
Market Share Insights
Which Chamber Configuration Accounts for the Largest Share of the Asia-Pacific Prefilled Syringes Market?
Single-chamber syringes hold the largest share by chamber type, supported by their suitability for formulations that remain stable as stored liquids and their simpler configuration, which reduces the number of components and operations requiring qualification. On the other hand, dual-chamber syringes are expected to grow at the fastest pace during the forecast period, driven by applications requiring separation of formulation components until administration, including selected products requiring reconstitution.
Which Type of Needle System is Gaining the Most Ground in the Asia-Pacific Prefilled Syringes Market?
Staked-needle syringes hold the largest share by needle system, supported by their attached needle configuration, which eliminates a separate needle-attachment step and enables consistent administration for products designed around a specified needle. Moreover, Luer syringes are expected to grow at the fastest pace during the forecast period due to their detachable connection, which allows needle selection or attachment at the time of administration.
Which Therapeutic Area is at the Forefront of Asia-Pacific Prefilled Syringes Development?
Hematological disorders hold the largest share by therapeutic area owing to the widespread use of syringe-based treatments for anemia and other blood-related conditions, including darbepoetin alfa injection syringes for renal anemia. Infectious diseases are expected to grow at the fastest pace during the forecast period.
Country Analysis: Asia-Pacific's Leading Prefilled Syringes Market
China is Expected to Hold the Largest Share of the Market During the Forecast Period
China is expected to record the highest CAGR during the forecast period owing to the rising chronic disease prevalence, increasing biologics and biosimilars production, healthcare modernization, and growing adoption of self-administered injectable therapies. The country's expanding pharmaceutical manufacturing base and domestic prefilled syringe capabilities, including those of Shandong Weigao, are further supporting the development of the regional market.
Key Players Profiled in Asia-Pacific Prefilled Syringes Market
The Asia-Pacific prefilled syringes market includes medical-device manufacturers, pharmaceutical-packaging specialists, and providers combining container technology with manufacturing services, including Terumo, Nipro Corporation, Taisei Kako, and Shandong Weigao Group Medical Polymer.
Report Deliverables and Customization
The report includes complimentary Excel data packs covering market landscape analysis, product competitiveness, recent developments, patent analysis, KOL analysis, SWOT analysis and market sizing and forecast analysis. A complimentary PowerPoint presentation is available, and up to 15% customization can be requested subject to data availability.
Report Authorship
Author(s): Simriti Gupta and Pemba Lahmo. Both authors contribute to Roots Analysis's healthcare and pharma research practice, covering biologics discovery, development, and manufacturing market studies.
Independence and Non-Affiliation
This report is an independent work of market research and analysis published by Roots Analysis. It is not affiliated with, sponsored by, endorsed by, or reviewed by BD, SCHOTT Pharma, Gerresheimer, Nipro Corporation, and Shandong Weigao Group Medical Polymer, or any other pharmaceutical company, drug brand, or regulatory body referenced within it. No content in this report should be construed as medical advice. Roots Analysis maintains its own proprietary primary research process, and does not receive compensation from any company profiled within the report, in exchange for inclusion or favorable characterization.
